Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06029998 · ClinicalTrials.gov registry record · Phase 2

Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion

A Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by University of Utah.

Recruiting
Registry status
Phase 2
Development phase
22
Enrollment target
1
Study location

NCT06029998 is a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by University of Utah. The registered enrollment target is 22 participants, below the 198-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06029998, a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by University of Utah.

RECRUITING
Registry status
Phase 2
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to test the anti-tumor activity of bortezomib in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC) with PTEN Deletion. The main question\[s\] it aims to answer is if the use of bortezomib will result in a decline in PSA for participants. Participants will receive a sub-cutaneous injection of bortezomib for up 8 cycles. Each cycle is about 21 days.

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer

Interventions

  • DRUG Bortezomib

Study Locations (1)

Utah

  • Huntsman Cancer Institute/University of Utah - Salt Lake City

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2024-03-11
Est. Completion 2028-12
Phase Phase 2

Sponsor

University of Utah

818 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06029998

The ClinicalTrials.gov registry entry for NCT06029998 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (89% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Bortezomib is the first listed.

NCT06029998 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.

Frequently Asked Questions

What is clinical trial NCT06029998 about?

NCT06029998 is a clinical study titled "Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion". The goal of this clinical trial is to test the anti-tumor activity of bortezomib in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC) with PTEN Deletion. The main question\[s\] it aims to answer is if the use of bortezomib will result in a decline in PSA for participants. P...

What is the current status of trial NCT06029998?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2024-03-11. Estimated completion is 2028-12.

What conditions does trial NCT06029998 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.

What interventions are being tested in trial NCT06029998?

The interventions under investigation include: Bortezomib (DRUG).

Who is sponsoring clinical trial NCT06029998?

This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06029998 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Castration-Resistant Prostate Cancer

All registered trials for this condition

Utah

All trials with a study site in Utah

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.